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The Best Laid Scheme?*Timothy D. Henry, MD,y Heidi J. Reich, MD,y Andreas M. Zeiher, MDzSEE PAGE 1424M ore than 5.8 million U.S. adults have heartfailure, including an estimated 250,000 to500,000 with end-stage heart failure re-
fractory to medical management (1). More than
2,400 durable, FDA-approved mechanical circulatory
support devices are implanted annually in the United
States (2). The rising rate of device implantations re-
ﬂects the improved survival and quality-of-life bene-
ﬁts that devices offer, although the 2-year survival
rates have plateaued at 70% (2). The most recent
INTERMACS (Interagency Registry for Mechanically
Assisted Circulatory Support) report (2) found that
42% of durable devices are implanted as destina-
tion therapy and only 1% of patients with devices
implanted as a bridge-to-heart transplantation expe-
rienced recovery at 1 year. Preclinical investigations
that demonstrate the capability of cell therapy to
improve myocardial perfusion and function in both
post-myocardial infarction and heart failure models
have stimulated optimism regarding the use of cell
therapy for patients with advanced heart failure
(3–5). In particular, there has been enthusiasm for the
use of stem or progenitor cells in patients undergoing
left ventricular assist device (LVAD) implantation.
This offers the dual opportunity to examine cardiac
tissue in patients undergoing heart transplantation
to obtain insights into the mechanism of beneﬁt, as
well as the potential to improve myocardial recovery*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
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by the TSFRE Braunwald Fellowship.(6). Despite evidence from preclinical models and
early clinical trials, considerable controversy remains
regarding the magnitude of beneﬁt and the mecha-
nisms of effect with cell therapy (7–9).
The ﬁrst successful report of combined cell therapy
and LVAD implantation was in this Journal in 2003,
when Pagani et al. (10) treated 5 ischemic cardio-
myopathy patients undergoing LVAD implantation
with autologous skeletal myoblasts and reported that
3 of 4 patients undergoing cardiac transplantation
had evidence of engraftment, including 1 with evi-
dence for small vessel formation. In the ensuing
12 years, <30 additional patients with ischemic car-
diomyopathy undergoing LVAD implantation in
combination with cell therapy have been reported in
the literature without further histopathological
assessment of neovasculogenesis (6).In this issue of the Journal, Stempien-Otero et al.
(11) report the histopathological results following
injection of autologous CD34þ, CD34, bone marrow
mononuclear cells, and vehicle into 4 quadrants of
a 1-cm diameter area of myocardium immediately
before LVAD implantation in 6 patients with ischemic
cardiomyopathy (12). Only 7 of 26 patients scheduled
for LVAD as a bridge to transplantation were
recruited, 1 was too unstable for injection, and
another had insufﬁcient CD34þ cells for injection. The
period for recruitment of the trial is not reported.
Compared with 13 “control” patients who underwent
LVAD implantation without injections, the 6 patients
receiving cell injections had similar blood product
utilization and ventricular arrhythmias within the
ﬁrst postoperative week without a death or reopera-
tion in either group, supporting the feasibility and
safety of this approach.
In contrast to the pro-angiogenic, anti-ﬁbrotic, and
anti-inﬂammatory effects reported in preclinical
models with CD34þ cells, the authors report reduction
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gions injected with CD34þ cells relative to vehicle and
no signiﬁcant differences in ﬁbrosis or inﬂammation
based on histopathological evaluation at the time of
transplantation 42 to 374 days later. They do ﬁnd a
reduction in activated myoﬁbroblasts in both the
CD34þ and CD34 segments. These results conﬂict
with previous preclinical studies that describe
enhanced neovasculogenesis in animal models of
ischemic heart disease. For example, in a rat model of
acute myocardial infarction, intramyocardial injec-
tion with 5  105 cells/kg of CD34þ cells resulted in
increased capillary density, reduced ﬁbrosis, and
preserved cardiac function with higher fractional
shortening and regional wall motion scores (6). The
extensive preclinical data supporting an improve-
ment in myocardial perfusion with CD34þ cells are
supported by clinical trial results, which are consis-
tent with an improvement in myocardial perfusion
(7,8). In particular, a double-blind trial using intra-
myocardial injections of CD34þ cells in 167 patients
with refractory angina resulted in a signiﬁcant
improvement in angina and exercise tolerance (12).
So, how do we explain this discrepancy between
“mice and men”? Preclinical models are designed
to maximize homogeneity with same sex, genetic
makeup, age, and absence of underlying coronary
atherosclerosis, cardiovascular risk factors, and med-
ications, which confound clinical trial results. Is this a
case in which the preclinical models are not pertinent
and/or misleading, or are there limitations with the
human model?
Failure to demonstrate an effect should not be
equated with proving the absence of an effect. As the
authors acknowledge, the results of this small study
should be interpreted with caution. Appropriate
sample size to detect clinically relevant differences
and minimize likelihood of type I and type II statistical
errors was not achieved. The timing of harvest of the
tissue varied from 42 to 374 days after cell injection.
Thus, given the high spatiotemporal variation in the
vascular niche controlling organ regeneration, po-
tential effects simply may have been missed (13).
There are a number of additional limitations to the
current trial beyond the small numbers and timing of
histopathological evaluation, including cell potency,
cell dose, variability in the areas treated, assessment
of vascular tissue, as well as the end-stage nature of
the disease.
An investigation into the mechanism to explain an
observed effect is strengthened by ﬁrst optimizing
and standardizing efﬁcacy. The number and potency
of autologous stem cells decline with age and car-
diovascular risk factors. In this trial, patients wereolder, 5 of 6 had diabetes, the percentage of CD34þ
cells ranged from 0.6% to 10.8% and there was no
measure of cell potency. The major limitation would
appear to be the low cell dose: the CD34þ cell dose
was 0.5  106 CD34þ, which is 70 to 80 times lower
than the effective dose established in rats (4) and 10
to 15 times lower than the dose used in the refractory
angina trial (12) based on a 70-kg human. In fact,
published data in healthy, young animals have
indicated that a dose of <105 cells/kg had
no measureable effect. Reduced cell efﬁcacy and
dramatically reduced doses may very well explain
the negative ﬁndings reported in this study. Would
a 1-mg dose of aspirin be effective in acute coro-
nary syndromes or with percutaneous coronary
intervention?
Potency of the cellular product was not tested with
respect to its angiogenic potential before initiating the
clinical study (14). Unfortunately, without knowing
the potency of a therapeutic agent, it is essentially
impossible to draw any meaningful conclusions. This
is speciﬁcally pertinent for the use of “biologicals,”
which are profoundly affected by inherent patient
factors, as is the case for autologous cellular products.
Another potential limitation is the end-stage na-
ture and heterogeneity of ischemic cardiomyopathy.
Injection sites were selected based on 50% to 75%
perfusion by technetium scan. Location heterogene-
ity alone might explain any observed differences
attributed here to treatment effect given the small
sample size especially in combination with the low
number of cells and signiﬁcant delay to histopath-
ological examination. Evidence suggests that the
predominant mechanism of beneﬁt is paracrine via
the recruitment of endogenous cells. However, the
expression of CD31, which was used to characterize
endothelial cells, is not limited to vascular tissue, but
it is also found on myeloid cells including mono-
cytes and macrophages making interpretation of the
observed results even more cumbersome.
Finally, very end-stage ischemic cardiomyopathy
may be a particularly challenging environment. In
fact, these patients rarely exhibit reverse remodeling
with unloading the heart by LVAD implantation.
We are left with the following the possibilities: 1)
preclinical studies are not predictive; 2) the present
clinical model was ﬂawed; or 3) the ﬁndings from
preclinical studies and the present clinical study are
both accurate but the preclinical “mice” models are
not relative to “men”?
The current research climate in cell therapy en-
courages traducing translation. However, each of
the explanations—mechanistic differences, sampling
error, limitations of the human model—must all be
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In this case, the “absence of evidence is not evi-
dence of absence” paradigm is not the end of the
conundrum but the needle pointing the way to the
solution.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Timothy D. Henry, Cedars-Sinai Heart Institute, 127
South San Vicente Boulevard, A3100, Los Angeles,
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